<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6092710</article-id><article-id pub-id-type="doi">10.3389/fphar.2018.00888</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>LncRNA-AK012226 Is Involved in Fat Accumulation in db/db Mice Fatty Liver and Non-alcoholic Fatty Liver Disease Cell Model </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xingtian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/476972/overview"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yangzhi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/476972/overview"/></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ting</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Chengxin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/476520/overview"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Ganxiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Yun</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/506888/overview"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shiming</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nie</surname><given-names>Yuqiang</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/465678/overview"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/458011/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Cadre Health Care, Guangdong Pharmaceutical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Guangzhou Institute of Cardiovascular Disease, The Second Affiliated Hospital of Guangzhou Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Gastroenterology, Guangzhou First People’s Hospital, Guangzhou Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><text><SENT sid="1" pm="."><plain>Edited by: Hua Wang, Anhui Medical University, China </plain></SENT>
</text></p></fn><fn fn-type="edited-by"><p><text><SENT sid="2" pm="."><plain>Reviewed by: Feng Li, Baylor College of Medicine, United States; Angelo A. </plain></SENT>
<SENT sid="3" pm="."><plain>Izzo, Università degli Studi di Napoli Federico II, Italy </plain></SENT>
</text></p></fn><corresp id="c001">*Correspondence: Hui Yang, <email>yanghui@gzhmu.edu.cn</email></corresp><fn fn-type="other" id="fn002"><p><text><SENT sid="4" pm="."><plain>†These authors have contributed equally to this work. </plain></SENT>
</text></p></fn><fn fn-type="other" id="fn003"><p><text><SENT sid="5" pm="."><plain>This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>08</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>888</elocation-id><history><date date-type="received"><day>12</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 Chen, Xu, Zhao, Chen, Gu, Yu, Chen, Zhong, He, Liu, Nie and Yang.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Chen, Xu, Zhao, Chen, Gu, Yu, Chen, Zhong, He, Liu, Nie and Yang</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>Instances of obesity and related metabolic abnormalities are increasing across the world. </plain></SENT>
<SENT sid="7" pm="."><plain>Non-alcoholic fatty liver disease (NAFLD) is a common disorder in obese people and is becoming the leading cause of hepatocellular carcinoma. </plain></SENT>
<SENT sid="8" pm="."><plain>Recently, long non-coding RNAs (lncRNAs) have been proven to play remarkable roles in numerous biological processes and human diseases, including NAFLD. </plain></SENT>
<SENT sid="9" pm="."><plain>However, the function of lncRNA in NAFLD pathogenesis remains largely unknown. </plain></SENT>
<SENT sid="10" pm="."><plain>The aim of this study was to explore the lncRNA expression profile in NAFLD mice and to identify novel lncRNAs involved in the pathogenesis of NAFLD. </plain></SENT>
<SENT sid="11" pm="."><plain>We performed microarray analysis to compare the expression profiles of lncRNAs and mRNAs in the liver of diabetic db/db mice with NAFLD and normal mice. </plain></SENT>
<SENT sid="12" pm="."><plain>A total of 3360 lncRNAs (2048 up-regulated and 1312 down-regulated) and 2685 mRNAs (1195 up-regulated and 1490 down-regulated) were found to be differentially expressed between the NAFLD and control groups. </plain></SENT>
<SENT sid="13" pm="."><plain>Real-time PCR validation of five differentially expressed lncRNAs in the liver samples was consistent with the microarray results. </plain></SENT>
<SENT sid="14" pm="."><plain>Besides, the up-regulated lncRNA, AK012226, was also significantly increased in an NCTC1469 NAFLD cellular model. </plain></SENT>
<SENT sid="15" pm="."><plain>Thus, the up-regulated lncRNA, AK012226, was chosen for subsequent studies. </plain></SENT>
<SENT sid="16" pm="."><plain>A co-expression network of AK012226-mRNAs was constructed and bioinformatic analysis of these co-expressed mRNAs indicated that they were enriched in the PPAR signaling pathway. </plain></SENT>
<SENT sid="17" pm="."><plain>Furthermore, Nile red staining and flow cytometry analysis revealed that knockdown of AK012226 by siRNA significantly reduced the lipid accumulation in the NCTC1469 cells treated with free fatty acids. </plain></SENT>
<SENT sid="18" pm="."><plain>In conclusion, the present study identifies the dysregulated lncRNAs and mRNAs involved in NAFLD, and in particular, a novel lncRNA, AK012226, was identified to be associated with lipid accumulation in NAFLD. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>lncRNA</kwd><kwd>AK012226</kwd><kwd>non-alcoholic fatty liver</kwd><kwd>microarray</kwd><kwd>lipid accumulation</kwd></kwd-group></SecTag><funding-group><award-group><funding-source id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content></funding-source><award-id rid="cn001">81372634</award-id><award-id rid="cn001">81600350</award-id></award-group></funding-group><counts><fig-count count="7"/><table-count count="3"/><equation-count count="0"/><ref-count count="34"/><page-count count="12"/><word-count count="0"/></counts></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="19" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="20" pm="."><plain>Instances of obesity and related metabolic syndrome are increasing around the world. </plain></SENT>
<SENT sid="21" pm="."><plain>According to the Global Health Observatory (GHO) data from World Health Organization (WHO), an estimated 600 million adults, accounting for approximately 13% of the world’s adult, were obese in 2014; this number has more than doubled since 1980 (WHO, 2014). </plain></SENT>
<SENT sid="22" pm="."><plain>Because of strong association with obesity, non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease, worldwide. </plain></SENT>
<SENT sid="23" pm="."><plain>It is estimated that its prevalence is 20–30% in the general population and 70% in patients with type 2 diabetes and is strikingly increased to 90–95% in obese people (Non-alcoholic Fatty Liver Disease Study Group et al., 2015; Portillo-Sanchez et al., 2015; Younossi et al., 2016). </plain></SENT>
<SENT sid="24" pm="."><plain>Thus, NAFLD is regarded as the hepatic manifestation of metabolic syndrome. </plain></SENT>
<SENT sid="25" pm="."><plain>Moreover, NAFLD is a risk factor for hepatocellular carcinoma (HCC), accounting for up to 25% of the cases of HCC in the western countries, and has become one of the most important public health problems (Michelotti et al., 2013). </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Non-alcoholic fatty liver disease includes a spectrum of diseases ranging from simple steatosis to steatohepatitis, advanced fibrosis, and cirrhosis (Anstee et al., 2011). </plain></SENT>
<SENT sid="27" pm="."><plain>However, the mechanism underlying the pathogenesis of NAFLD has not yet been fully elucidated and, thus, there are no effective medical interventions to completely cure NAFLD. </plain></SENT>
<SENT sid="28" pm="."><plain>Currently, the treatment for NAFLD remains limited, and mainly includes lifestyle alteration and body weight control; however, such strategies have poor compliance. </plain></SENT>
<SENT sid="29" pm="."><plain>A better understanding of the pathogenesis of NAFLD and devising of effective prevention and treatment modalities are, therefore, urgently required. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>Long non-coding RNAs (lncRNAs) refer to RNA transcripts longer than 200 nucleotides that lack protein-coding capacity (Wilusz et al., 2009). </plain></SENT>
<SENT sid="31" pm="."><plain>Recently, emerging evidence has proved that lncRNAs play remarkable roles in numerous biological processes (Mercer et al., 2009; Wang and Chang, 2011; Wang et al., 2011; Rinn and Chang, 2012; Li et al., 2015), including cell differentiation, tumorigenesis, immune response, and hepatic lipid metabolism through transcriptional and epigenetic gene regulation. </plain></SENT>
<SENT sid="32" pm="."><plain>Currently, many lncRNAs are known to be involved in liver diseases. </plain></SENT>
<SENT sid="33" pm="."><plain>For example, H19, HULC, and HOTAIR are lncRNAs that are upregulated in the hepatocellular carcinomas and promote tumor growth through various mechanisms. </plain></SENT>
<SENT sid="34" pm="."><plain>Additionally, in a recent study, we identified a new lncRNA, uc002mbe.2, which plays a critical role in trichostatin A-induced apoptosis of HCC cells (Yang et al., 2013; Chen T. et al., 2017). </plain></SENT>
<SENT sid="35" pm="."><plain>Moreover, increasing evidence suggests that lncRNA may also play key roles in lipid metabolism. Li et al. (2015) identified a liver-enriched lncRNA, lncLSTR, which regulates apoC2 expression via FXR-mediated pathway. </plain></SENT>
<SENT sid="36" pm="."><plain>Depletion of lncLSTR increases apoC2 expression, initiating LPL activation and enhances serum triglycerides clearance (Li et al., 2015). </plain></SENT>
<SENT sid="37" pm="."><plain>However, the roles of lncRNAs in the pathogenesis of NAFLD remain largely unknown. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>In this study, we performed a microarray analysis to compare the liver lncRNA and mRNA profiles in diabetic db/db mice and normal mice. </plain></SENT>
<SENT sid="39" pm="."><plain>Using several approaches for validation and mechanistic elucidation, we demonstrate that an lncRNA, AK012226, plays a crucial role in lipid accumulation and, thereby, in the pathogenesis of NAFLD. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s1"><title><text><SENT sid="40" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec><title><text><SENT sid="41" pm="."><plain>Animal Studies </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>Three female C57BLKS/J db/db mice and three female C57BLKS/J mice aged 4 weeks, purchased from Changzhou Cavens Laboratory Animal, Co., China were used as the NAFLD and control groups, respectively. </plain></SENT>
<SENT sid="43" pm="."><plain>The mice were housed in a pathogen-free barrier facility with a 12 h light/dark cycle and received standard diet, and free access to water and food. </plain></SENT>
<SENT sid="44" pm="."><plain>At the age of 8 weeks, serum samples were collected prior to the sacrifice of mice and liver was harvested for further studies. </plain></SENT>
</text></p><p><text><SENT sid="45" pm="."><plain>This study was approved by the Ethical Committee of Guangzhou Medical University, China. </plain></SENT>
<SENT sid="46" pm="."><plain>All the animal experiments complied with the standard ethical guidelines prescribed by the ethical committees mentioned above. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="47" pm="."><plain>Hematoxylin and Eosin Staining </plain></SENT>
</text></title><p><text><SENT sid="48" pm="."><plain>Liver tissue samples were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 2 h, stored overnight in 10% formalin, and were embedded in paraffin. </plain></SENT>
<SENT sid="49" pm="."><plain>Cross-sections (5 μm) of the tissue were cut and used for staining with hematoxylin and eosin. </plain></SENT>
<SENT sid="50" pm="."><plain>Images were taken using a light microscope. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="51" pm="."><plain>Measurement of Blood Glucose and Liver Triglyceride Levels </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>Sera were obtained by centrifugation of blood at 1500 ×g for 10 min after coagulation. </plain></SENT>
<SENT sid="53" pm="."><plain>The levels of blood glucose were measured with an automated analyzer for clinical chemistry (Arkray, Kyoto, Japan). </plain></SENT>
<SENT sid="54" pm="."><plain>The triglycerides in the liver were measured using the methods described in the kits from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="55" pm="."><plain>RNA Preparation and Microarray Analysis </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>Total RNA was extracted from the liver of six mice (three NAFLD and control mice, each) using Trizol and treated with DNase I (Invitrogen, Carlsbad, CA, United States). </plain></SENT>
<SENT sid="57" pm="."><plain>The integrity of RNA was assessed by electrophoresis on denatured agarose gel. </plain></SENT>
<SENT sid="58" pm="."><plain>Mouse LncRNA Microarray V2.0 (Arraystar, Rockville, MD, United States) was used to study the profiles of mouse lncRNAs and protein-coding transcripts in the liver. </plain></SENT>
<SENT sid="59" pm="."><plain>Nearly 31,423 lncRNAs and 25,376 coding transcripts could be detected using second-generation LncRNA microarray. </plain></SENT>
<SENT sid="60" pm="."><plain>The LncRNAs are carefully collected from the most authoritative databases such as RefSeq, UCSC Knowngenes, Ensembl and many related literatures. </plain></SENT>
<SENT sid="61" pm="."><plain>Each transcript is represented by a specific exon or splice junction probe which can identify individual transcript accurately. </plain></SENT>
<SENT sid="62" pm="."><plain>Each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3′-bias using a random priming method (Arraystar Flash RNA Labeling Kit, Arraystar). </plain></SENT>
<SENT sid="63" pm="."><plain>The labeled cRNAs were hybridized onto a Mouse lncRNA Array v2.0 (8 × 60K, Arraystar). </plain></SENT>
<SENT sid="64" pm="."><plain>After extensive washing, the arrays were scanned by an Agilent G2505C Scanner. </plain></SENT>
<SENT sid="65" pm="."><plain>The Agilent Feature Extraction software (version 11.0.1.1) was used to analyze the acquired array images. </plain></SENT>
<SENT sid="66" pm="."><plain>The GeneSpringGXv11.5.1 software package (Agilent Technologies) offered quantile normalization and background correction. </plain></SENT>
<SENT sid="67" pm="."><plain>The differentially expressed lncRNAs and mRNAs between the two samples were identified through fold change filtering. </plain></SENT>
<SENT sid="68" pm="."><plain>Pathway and gene ontology (GO) analyses were performed to determine the roles of the differentially expressed mRNAs in these biological pathways and the GO terms, respectively. </plain></SENT>
<SENT sid="69" pm="."><plain>Finally, hierarchical clustering was performed to obtain distinguishable LncRNA and mRNA expression patterns among the samples. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="70" pm="."><plain>RNA Extraction and Quantitative Real-Time PCR </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>Total RNA from liver tissue samples and cultured cells was isolated using Trizol and treated with DNase I (Invitrogen, Carlsbad, CA, United States). </plain></SENT>
<SENT sid="72" pm="."><plain>In brief, quantitative real-time PCR was carried out to study lncRNA expression using the Prime Script RT Reagent Kit (TaKaRa, Dalian, China) and SYBR Premix Ex Taq (TaKaRa, Dalian, China). </plain></SENT>
<SENT sid="73" pm="."><plain>Real-time PCR was performed on ABI Prism 7300 real-time PCR system (Applied Biosystems, Foster City, CA, United States). </plain></SENT>
<SENT sid="74" pm="."><plain>The quantification analysis for target gene expression was performed using the relative quantification comparative CT method. </plain></SENT>
<SENT sid="75" pm="."><plain>The primers used for the real-time PCR are listed in Table 1. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="76" pm="."><plain>Oligonucleotide sequences of the quantitative real-time RT-PCR primers. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>Primer name </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>Sequence (5′→3′) </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>GAPDH </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>F: 5′ GTTGTCTCCTGCGACTTCA 3′R: 5′ GCCCCTCCTGTTATTATGG 3′ </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>AK012226 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>F: 5′ TCGTCTCCGAGCAGATTGTTG 3′R: 5′ TCGTCTCCGAGCAGATTGTTG 3′ </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>B430212C06Rik </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>F: 5′ TGGAGTCTTCCATTGGGAACTG 3′R: 5′ TGGCTTGTCTCAGCAAAGATACTC 3′ </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>Fabp3-ps1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>F: 5′ TCCTCACTCATCGCACCATG 3′R: 5′ AGCCCACACCGAGTGACTTC 3′ </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>NR-040532 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>F: 5′ GAGAGACACTGGGACTGGCTTG 3′R: 5′ TGTGAGGTGCTACAGAGTTGGTC 3′ </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>AK052193 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>F: 5′ ACAAGTGAGTATCTGGGCTTTATCC 3′R: 5′ GGTTTGTCCTCTGACCTCCACTC 3′ </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>ENSMUST0000139794 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>F: 5′ AGAACGGATGACGCTGCCTC 3′R: 5′ TGGCAGCCGTGTGGAACTAG 3′ </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></SecTag></sec><sec><title><text><SENT sid="93" pm="."><plain>Nile Red Staining and Flow Cytometry Analysis </plain></SENT>
</text></title><p><text><SENT sid="94" pm="."><plain>After the different treatments, cells were fixed with 4% paraformaldehyde at 26°C for 15 min, and incubated for 15 min with 1 μM Nile red dye working fluid (a hydrophobic dye that accumulates in lipid droplets). </plain></SENT>
<SENT sid="95" pm="."><plain>Thereafter, DAPI was added to stain the nucleus and the cells were examined by a confocal microscope (Carl Zeiss Company, Germany) or a digitized fluorescent microscope (BD Bio-sciences Pharmingen, San Diego, CA, United States). </plain></SENT>
<SENT sid="96" pm="."><plain>For quantitative analysis, cells were washed with PBS, centrifuged, and suspended in 500 μM Nile red dye stained for 15 min. </plain></SENT>
<SENT sid="97" pm="."><plain>After repeated centrifugation, the cells were incubated under 5% CO2 at 37°C for 15 min and were analyzed the fluorescence intensity of each group using flow cytometry (BD bio-sciences Pharmingen, San Diego, CA, United States). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="98" pm="."><plain>Cell Culture and Treatment </plain></SENT>
</text></title><p><text><SENT sid="99" pm="."><plain>NCTC 1469 cells were bought from the Institute of Biochemistry and Cell Biology, Chinese Academy of Science (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (Mediatech, Herndon, VA, United States), supplemented with 10% (v/v) fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, United States) at 37°C under 5% CO2. </plain></SENT>
<SENT sid="100" pm="."><plain>The cells were treated with a mixture of 600 or 800 μM free fatty acids (FFAs; oleic acid:palmitic acid = 2:1) for 24 h to develop NAFLD cell model. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="101" pm="."><plain>siRNA Transfection </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>Scrambled siRNAs and predesigned siRNAs specific to different sites of lncRNA AK012226 were designed by the Robobio Company (Guangzhou, China). </plain></SENT>
<SENT sid="103" pm="."><plain>Cell transfection was conducted using LipofectamineTM RNAiMAX reagent (Invitrogen, Carlsbad, CA, United States) with lncRNA AK012226 siRNA. </plain></SENT>
<SENT sid="104" pm="."><plain>After 48 h, the cells were harvested to evaluate the efficiency of AK012226 lncRNA knockdown by quantitative real-time PCR. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="105" pm="."><plain>LncRNA–mRNA Co-expression Network </plain></SENT>
</text></title><p><text><SENT sid="106" pm="."><plain>The lncRNA–mRNA co-expression network was constructed based on the correlation between the lncRNA-AK012226 and the differentially expressed mRNAs using Pearson’s correlation coefficient. </plain></SENT>
<SENT sid="107" pm="."><plain>The lncRNA–mRNA pairs with correlation coefficient significantly more than 0.85 were selected to construct the network (Pujana et al., 2007; Prieto et al., 2008). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="108" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="109" pm="."><plain>Differentially expressed lncRNAs and mRNAs with statistical significance were identified through Volcano Plot filtering. </plain></SENT>
<SENT sid="110" pm="."><plain>The fold change &gt; 2.0 and p-value &lt; 0.05 was set for the threshold of up- and down-regulated genes. </plain></SENT>
<SENT sid="111" pm="."><plain>The data are presented as mean ± SD. </plain></SENT>
<SENT sid="112" pm="."><plain>Statistical analysis was performed using Student’s t-test for two-group comparison. </plain></SENT>
<SENT sid="113" pm="."><plain>Significance was defined as p &lt; 0.05. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="114" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="115" pm="."><plain>Animal Model of Non-alcoholic Fatty Liver Disease </plain></SENT>
</text></title><p><text><SENT sid="116" pm="."><plain>Due to the dysfunction of leptin receptor, the db/db mice develop hyperphagia-induced obesity, type 2 diabetes, and non-alcoholic fatty liver (NAFL) spontaneously. </plain></SENT>
<SENT sid="117" pm="."><plain>Obvious hepatic steatosis of db/db mice was observed by H&amp;E staining (Figure 1A). </plain></SENT>
<SENT sid="118" pm="."><plain>Moreover, the body weight (48.40 ± 0.4899 vs. 25.93 ± 1.7913, p &lt; 0.0001), the liver weight (4.443 ± 0.9686 vs. 1.237 ± 0.1621, p = 0.0099), the hepatic triglyceride level (0.7144 ± 0.0236 vs. 0.4016 ± 0.0206, p &lt; 0.0001), and the blood glucose level (25.90 ± 5.1554 vs. 6.850 ± 1.3766, p = 0.0072) were significantly elevated in the db/db mice group compared to those in the control group (Figures 1B–E). </plain></SENT>
<SENT sid="119" pm="."><plain>Taken together, the db/db mice exhibited obesity, type 2 diabetes, and NAFL. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>FIGURE 1</label><caption><p><text><SENT sid="120" pm="."><plain>Pathological changes in db/db and control mice. (A) Representative images of the hematoxylin and eosin stained liver of db/db mice. (B) Body weight, (C) liver weight, (D) blood glucose level, and (E) hepatic triglyceride level of db/db and control mice. </plain></SENT>
<SENT sid="121" pm="."><plain>The values in bar graphs are means ± SD. ∗p &lt; 0.05. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-09-00888-g001"/></fig></SecTag></sec><sec><title><text><SENT sid="122" pm="."><plain>Expression Profiles of lncRNAs and mRNAs in Mice With NAFL </plain></SENT>
</text></title><p><text><SENT sid="123" pm="."><plain>To determine the expression profiles of lncRNAs and mRNAs in mice with NAFL, the Mouse LncRNA Microarray V2.0 (Arraystar, Rockville, MD, United States) were used. </plain></SENT>
<SENT sid="124" pm="."><plain>The microarray data is available in Gene Expression Omnibus (GSE108228). </plain></SENT>
<SENT sid="125" pm="."><plain>The scatter plot and volcano plot analyses are shown in Figure 2. </plain></SENT>
<SENT sid="126" pm="."><plain>It was found that a total of 3360 lncRNAs (2048 upregulated and 1312 downregulated) and 2685 mRNAs (1195 upregulated and 1490 downregulated) were differentially expressed between the NAFLD and control groups. </plain></SENT>
<SENT sid="127" pm="."><plain>Hierarchical clustering was performed to analyze the gene expression patterns between the samples. </plain></SENT>
<SENT sid="128" pm="."><plain>A distinguishable pattern was observed between the NAFLD and control groups (Figure 3). </plain></SENT>
<SENT sid="129" pm="."><plain>Among these aberrant expressed lncRNAs, there were 228/206 exon sense-overlapping (up-/down-regulated lncRNAs), 51/92 intronic sense-overlapping, 352/141 natural antisense, 253/132 intronic antisense, 301/101 bidirectional, and 862/640 intergenic lncRNAs (Figure 2E). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" position="float"><label>FIGURE 2</label><caption><p><text><SENT sid="130" pm="."><plain>Profiles of lncRNAs and coding gene RNAs in non-alcoholic fatty liver disease (NAFLD) mice and control mice. </plain></SENT>
<SENT sid="131" pm="."><plain>Total RNA from three db/db mice and three control mice were isolated and gene expression was determined by Mouse LncRNA Microarray V2.0. </plain></SENT>
<SENT sid="132" pm="."><plain>The scatter plot was used for assessing the reproducibility of long non-coding RNA (lncRNA; A) and coding gene (B) expression. </plain></SENT>
<SENT sid="133" pm="."><plain>The values on x and y axis in the scatter plot are the averaged normalized signal values of groups of samples (log 2 scaled). </plain></SENT>
<SENT sid="134" pm="."><plain>Volcano plot analysis of the microarray chip data on differentially expressed lncRNAs (C) and coding gene (D) between the NAFLD and control mice. </plain></SENT>
<SENT sid="135" pm="."><plain>The vertical green lines correspond to a 2.0-fold up or down regulation whereas the horizontal green line represents a value of 0.05. </plain></SENT>
<SENT sid="136" pm="."><plain>The red dots to the left and right of the vertical green lines indicate more than 2.0-fold change and represent differential expression with statistical significance. </plain></SENT>
<SENT sid="137" pm="."><plain>Statistical significance was defined as fold change &gt; 2.0 and p-value &lt; 0.05 between the NAFLD and control groups. (E) Distribution of differentially expressed lncRNAs according to their classification. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-09-00888-g002"/></fig></SecTag><SecTag type="FIG"><fig id="F3" position="float"><label>FIGURE 3</label><caption><p><text><SENT sid="138" pm="."><plain>Heat map of the differentially expressed lncRNAs (A) and coding genes (B) in NAFLD mice and control mice. </plain></SENT>
<SENT sid="139" pm="."><plain>Each row represents the relative expression level of a single lncRNA or mRNA, and each column represents a single sample. </plain></SENT>
<SENT sid="140" pm="."><plain>High relative expression is indicated by red color and low relative expression is indicated by green color. </plain></SENT>
<SENT sid="141" pm="."><plain>F1-3: NAFLD group. </plain></SENT>
<SENT sid="142" pm="."><plain>N1-3: control group. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-09-00888-g003"/></fig></SecTag></sec><sec><title><text><SENT sid="143" pm="."><plain>Validation of the Microarray Data Using Quantitative Real-Time PCR </plain></SENT>
</text></title><p><text><SENT sid="144" pm="."><plain>To confirm the microarray results, five differentially expressed lncRNAs (AK012226, B430212C06Rik, Fabp3-ps1, NR-040532, and AK052193) were selected for qPCR validation in the liver samples of the NAFLD and control groups. </plain></SENT>
<SENT sid="145" pm="."><plain>As presented in Figure 4, the qPCR results were generally consistent with the microarray data, confirming the reliability of the microarray result (Figure 4). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F4" position="float"><label>FIGURE 4</label><caption><p><text><SENT sid="146" pm="."><plain>Comparison of microarray data and real-time quantitative polymerase chain reaction (qPCR) data for five selected differentially expressed lncRNAs in liver samples between NAFLD mice and control mice. </plain></SENT>
<SENT sid="147" pm="."><plain>The qPCR results are generally consistent with the microarray data. </plain></SENT>
<SENT sid="148" pm="."><plain>The results are the means of three independent experiments. </plain></SENT>
<SENT sid="149" pm="."><plain>The values in bar graphs are means ± SD. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-09-00888-g004"/></fig></SecTag><p><text><SENT sid="150" pm="."><plain>In addition, we also examined the expression of differentially expressed lncRNAs in the mouse NAFLD cellular model. </plain></SENT>
<SENT sid="151" pm="."><plain>Murine NCTC 1469 hepatocytes were exposed to FFA at a concentration of 600 or 800 μM for 24 h to establish the in vitro NAFLD model. </plain></SENT>
<SENT sid="152" pm="."><plain>Obvious lipid accumulation, as detected by Nile red staining, was observed in cells treated with FFA compared to that in the control cells. </plain></SENT>
<SENT sid="153" pm="."><plain>This was further confirmed by flow cytometric analysis of the fluorescence intensity (Figures 5A,B). </plain></SENT>
<SENT sid="154" pm="."><plain>Subsequently, qPCR of four dysregulated lncRNAs (AK012226, NR-040532, Fabp3-ps1, and ENSMUST0000139794) was conducted in the mouse NAFLD cellular model. </plain></SENT>
<SENT sid="155" pm="."><plain>However, only the expression of the up-regulated lncRNA-AK012226 was consistent with the microarray data, whereas the others did not show differential expression (Figure 5C). </plain></SENT>
<SENT sid="156" pm="."><plain>Thus, the up-regulated lncRNA, AK012226, was chosen for subsequent experiments. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F5" position="float"><label>FIGURE 5</label><caption><p><text><SENT sid="157" pm="."><plain>Expression of four differentially expressed lncRNAs in NCTC1469 cells treated with free fatty acids (FFAs). </plain></SENT>
<SENT sid="158" pm="."><plain>NCTC1469 cells were treated with FFAs at a concentration of 600 or 800 μM or dimethyl sulfoxide (DMSO) as control for 24 h. </plain></SENT>
<SENT sid="159" pm="."><plain>Obvious lipid accumulation was observed in FFA-treated cells compared to that in the control cells as detected by Nile red staining (A) and flow cytometry analysis (B). (C) Quantitative real-time PCR of four up-regulated genes (AK012226, NR-040532, Fabp3-ps1, and ENSMUST00000139794) were performed to examine their expression levels. </plain></SENT>
<SENT sid="160" pm="."><plain>AK012226 expression was significantly increased in the NCTC1469 cells treated with FFAs. </plain></SENT>
<SENT sid="161" pm="."><plain>The results are the means of three independent experiments. </plain></SENT>
<SENT sid="162" pm="."><plain>The values in bar graphs are means ± SD. ∗p &lt; 0.05. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-09-00888-g005"/></fig></SecTag></sec><sec><title><text><SENT sid="163" pm="."><plain>Construction of AK012226-mRNA Co-expression Network and Bioinformatic Analysis </plain></SENT>
</text></title><p><text><SENT sid="164" pm="."><plain>To ascertain the correlation between lncRNA AK012226 and the differentially expressed mRNAs, a co-expression network was built. </plain></SENT>
<SENT sid="165" pm="."><plain>A total of 218 mRNAs co-expressed with AK012226 with p-value &lt; 0.05 and an absolute value of correlation coefficient &gt; 0.85 was identified. </plain></SENT>
<SENT sid="166" pm="."><plain>The top 10 positively/negatively correlated mRNAs are listed in Tables 2, 3. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><text><SENT sid="167" pm="."><plain>Top 10 positively correlated mRNAs. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>Accession </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>Gene symbol </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>Definition </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>Correlation </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>p-Value </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>NM_001102578 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>Vmn2r75 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>Vomeronasal 2, receptor 75 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>0.9994003 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>0.002777778 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>NM_029116 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>Kbtbd11 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>Kelch repeat and BTB (POZ) domain containing 11 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>0.99860294 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>0.001388889 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>NM_008509 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>Lpl </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>Lipoprotein lipase </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>0.998057075 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>0.004166667 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>NM_007545 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>Hrk </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>BCL2 interacting protein (contains only BH3 domain) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>0.997957619 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>0.001388889 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>NM_175340 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>Nhlrc1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>NHL repeat containing 1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>0.997585415 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>0.004166667 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>NM_009988 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>Cxadr </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>Coxsackie virus and adenovirus receptor </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>0.997267846 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>0.002777778 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>NM_212457 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>Bex4 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>Brain expressed X-linked 4 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>0.997135417 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>0.002777778 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>NM_001081651 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>Rab42 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>Member RAS oncogene family </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>0.99698408 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>0.004166667 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>NM_029011 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>Pyroxd2 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>Pyridine nucleotide-disulfide oxidoreductase domain 2 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>0.996300767 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>0.001388889 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>NM_001033148 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>1700029J07Rik </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>RIKEN cDNA 1700029J07 gene </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>0.995910932 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>0.004166667 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><text><SENT sid="223" pm="."><plain>Top 10 negatively correlated mRNAs. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>Accession </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>Gene symbol </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>Definition </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>Correlation </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>p-Value </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>NM_009502 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>Vcl </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>Vinculin </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>-0.955008039 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>0.016666667 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>NM_133203 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Klra17 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>Killer cell lectin-like receptor, subfamily A, member 17 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>-0.94838445 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>0.033333333 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>NM_133882 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>C8b </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>Complement component 8, beta polypeptide </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>-0.944792307 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>0.038888889 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>NM_172306 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>Cyp4a12b </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Cytochrome P450, family 4, subfamily a, polypeptide 12B </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>-0.9397872 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>0.030555556 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>NM_007912 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>Egfr </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>Epidermal growth factor receptor </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>-0.938161248 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>0.047222222 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>NM_177406 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Cyp4a12a </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>Cytochrome P450, family 4, subfamily a, polypeptide 12a </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>-0.934294503 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>0.047222222 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>NM_153601 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>Lgsn </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>Lens protein with glutamine synthetase domain </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>-0.929686267 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>0.041666667 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>NM_001159415 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>Ces3b </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>Carboxylesterase 3B </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>-0.926505763 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>0.025 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>NM_177620 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>Rin3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>Ras and Rab interactor 3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>-0.920528278 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>0.048611111 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>NM_001081174 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>Rsg1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>REM2 and RAB-like small GTPase 1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>-0.919993451 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>0.029166667 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="279" pm="."><plain>The GO categories for each gene were derived from the GO website1. </plain></SENT>
<SENT sid="280" pm="."><plain>The categories comprised of three structured networks: biological processes, cellular components, and molecular function. </plain></SENT>
<SENT sid="281" pm="."><plain>Through the analysis of the GO terms, it was found that the co-expressed mRNAs were principally enriched in the following components: (1) chemokine secretion, (2) regulation of chemokine secretion, (3) positive regulation of vasodilation, (4) V(D)J recombination, and (5) response to gamma radiation in biological process. </plain></SENT>
<SENT sid="282" pm="."><plain>The top10 GO terms in biological process, cellular components, and molecular functions are shown in Figure 6. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F6" position="float"><label>FIGURE 6</label><caption><p><text><SENT sid="283" pm="."><plain>Bioinformatic analysis of mRNAs co-expressed with lncRNA-AK012226. (A) Gene ontology (GO) enrichment analysis of the co-expressed mRNAs. (B) KEGG pathway analysis of the co-expressed mRNAs. </plain></SENT>
<SENT sid="284" pm="."><plain>The horizontal axis represents -lg (p-value) of the GO terms and the pathway terms. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-09-00888-g006"/></fig></SecTag><p><text><SENT sid="285" pm="."><plain>The KEGG pathway analysis was also performed using the KEGG database2. </plain></SENT>
<SENT sid="286" pm="."><plain>The co-expressed mRNAs were associated with “PPAR signaling pathway,” “adherens junction,” “Chemical carcinogenesis,” “Metabolism of xenobiotics by cytochrome P450,” and “Bile secretion.” </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="287" pm="."><plain>LncRNA AK012226 Participates in the Development of NAFL in the Cellular Model </plain></SENT>
</text></title><p><text><SENT sid="288" pm="."><plain>To further explore the role of AK012226 in the development of NAFL, NCTC 1469 cells were transfected with two AK012226-siRNAs targeting different sites and were subsequently treated with 800 μM FFA. </plain></SENT>
<SENT sid="289" pm="."><plain>The qPCR results showed that the AK012226 expression was knocked down by about 70% in the transfected cells (Figure 7A). </plain></SENT>
<SENT sid="290" pm="."><plain>Next, we examined the cellular lipid droplets in the transfected NCTC 1469 cells exposed to 800 μM FFA. </plain></SENT>
<SENT sid="291" pm="."><plain>A striking decrease of lipid accumulation was observed in the transfected cells compared to that in the control cells by Nile red staining; this was further confirmed by flow cytometric analysis (Figures 7B,C). </plain></SENT>
<SENT sid="292" pm="."><plain>Taken together, the knockdown of AK012226 expression decreased the lipid accumulation in the FFA-treated NCTC cells, suggesting that AK012226 could play a functional role in the pathogenesis of NAFLD. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F7" position="float"><label>FIGURE 7</label><caption><p><text><SENT sid="293" pm="."><plain>Knockdown of AK012226 expression significantly decreased the lipid accumulation in NCTC1469 cells treated with FFAs. (A) AK012226 expression in NCTC1469 cells transfected with two siRNAs targeting different sites of AK012226, respectively, followed by 24-h FFA treatment. (B) AK012226 siRNA-transfected NCTC1469 cells were exposed to FFAs for 24 h and were subsequently examined by Nile red staining. (C) Flow cytometric analysis of fluorescence in transfected NCTC1469 cells treated for 24 h with FFAs and subsequently stained with Nile red. ∗∗p &lt; 0.01. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-09-00888-g007"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="294" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="295" pm="."><plain>Long non-coding RNAs participate in various biological processes, and the aberrant lncRNA expression can cause diverse diseases, especially cancers. </plain></SENT>
<SENT sid="296" pm="."><plain>Increasing evidence suggests that lncRNAs can act as oncogenes or tumor suppressor RNAs (Gibb et al., 2011; Shi et al., 2013). </plain></SENT>
<SENT sid="297" pm="."><plain>However, as of date, little is known about the roles of lncRNA in the pathogenesis of NAFLD. </plain></SENT>
<SENT sid="298" pm="."><plain>In the present study, we performed genome-wide lncRNA and mRNA microarray analyses of liver samples from diabetic NAFL mouse to identify novel lncRNAs involved in the pathogenesis of NAFLD, aimed at obtaining new insights for the development of new therapeutic approaches. </plain></SENT>
<SENT sid="299" pm="."><plain>Notably, we discovered a novel lncRNA, AK012226, which was up-regulated in the liver of the NAFL mouse and was observed to play a role in the lipid accumulation in vitro. </plain></SENT>
</text></p><p><text><SENT sid="300" pm="."><plain>Thus far, only a few studies have explored the role of lncRNAs in NAFLD. Sun et al. (2015) performed microarray experiments to analyze the profile of mRNAs and lncRNAs in patients with NAFLD, and 1735 lncRNAs and 1485 mRNAs were found to be differentially expressed in the NAFLD samples. </plain></SENT>
<SENT sid="301" pm="."><plain>A research from China (Chen Y. et al., 2017) involved microarrays in the high fat diet-induced NAFLD mice model and revealed several lncRNAs and mRNAs associated with lipogenesis through different pathways. </plain></SENT>
<SENT sid="302" pm="."><plain>Additionally, Chen et al. (2016) reported that lncRNA SRA could decrease lipolysis by repressing the expression of ATGL, leading to hepatic. </plain></SENT>
<SENT sid="303" pm="."><plain>However, the expression profiles of lncRNAs and mRNAs in our study were a bit different from those observed in the above-mentioned studies, which could be attributed to the different NAFLD model employed by us. </plain></SENT>
<SENT sid="304" pm="."><plain>Unlike the dietary mouse model of NAFLD used in several studies to perform genome wide analysis (Chen et al., 2016; Chen Y. et al., 2017), we employed the diabetic db/db mouse to establish the NAFLD animal model. </plain></SENT>
<SENT sid="305" pm="."><plain>Insulin resistance, frequently found in obesity and type 2 diabetes, is considered to be the most important factor in the pathogenesis of hepatic steatosis. </plain></SENT>
<SENT sid="306" pm="."><plain>Therefore, the animal model is a better for metabolic abnormalities, such as obesity, type 2 diabetes, and NAFLD (Sanches et al., 2015). </plain></SENT>
<SENT sid="307" pm="."><plain>The db/db mouse, defective in the leptin receptor gene, is a classic diabetic rodent model, manifesting hyperphagia, obesity, hyperlipidemia, insulin resistance, and hepatic steatosis (Tesch and Lim, 2011; Kitada et al., 2016). </plain></SENT>
<SENT sid="308" pm="."><plain>In the present study, our results indicated that the db/db mouse develop NAFL, which is consistent with the results obtained in other studies (Kim et al., 2015; Su et al., 2016). </plain></SENT>
<SENT sid="309" pm="."><plain>Thus, the db/db mouse is a proper animal model that mimics the metabolic syndrome-associated NAFLD in humans and is a suitable model to examine the role of lncRNAs in the pathogenesis of NAFLD. </plain></SENT>
</text></p><p><text><SENT sid="310" pm="."><plain>Notably, we identified a novel lncRNA, AK012226, which plays a functional role in lipid accumulation in the mouse NAFLD cellular model. </plain></SENT>
<SENT sid="311" pm="."><plain>AK012226, located on the sense strand on chromosome 14 of mouse, is an exon sense-overlapping lncRNA. </plain></SENT>
<SENT sid="312" pm="."><plain>Exon-sense overlapping lncRNA is an lncRNA category that can be considered as transcript variants of protein-coding mRNAs, as they overlap with a known annotated gene on the same genomic strand. </plain></SENT>
<SENT sid="313" pm="."><plain>The gene predicted to be associated with it is 1700112E06Rik. </plain></SENT>
<SENT sid="314" pm="."><plain>However, this gene is considered to be involved in melanocyte differentiation. </plain></SENT>
<SENT sid="315" pm="."><plain>Moreover, our results indicated that the knockdown of AK012226 expression significantly reduced the in vitro lipid accumulation. </plain></SENT>
<SENT sid="316" pm="."><plain>Hepatic steatosis has long been considered as a relatively benign state in NAFLD. </plain></SENT>
<SENT sid="317" pm="."><plain>Recent studies have proven that fatty liver is more vulnerable to injury from various causes (Adams et al., 2005). </plain></SENT>
<SENT sid="318" pm="."><plain>Hepatic lipid accumulation is also associated with the increase in endoplasmic reticulum stress markers (Neuschwander-Tetri, 2010). </plain></SENT>
<SENT sid="319" pm="."><plain>The accumulation of lipid can further aggravate the existing hepatic insulin resistance by generation of lipid-derived second messengers, such as diacylglycerol (DAG) and ceramides (Jornayvaz and Shulman, 2012). </plain></SENT>
<SENT sid="320" pm="."><plain>Thus, it is considered as the “first hit” in the pathogenesis of NAFLD (Day and James, 1998). </plain></SENT>
<SENT sid="321" pm="."><plain>Therefore, lipid overaccumulation within hepatocytes is crucial in NAFLD (Donnelly et al., 2005; Reccia et al., 2017). </plain></SENT>
</text></p><p><text><SENT sid="322" pm="."><plain>Recently, several lncRNAs involved in lipid metabolism have been identified. </plain></SENT>
<SENT sid="323" pm="."><plain>SPRY4-IT1, an lncRNA overexpressed in melanoma cells, negatively regulates triacylglycerol levels in melanoma cells and knockdown of SPRY4-IT1 can induce apoptosis via lipin 2-mediated alterations in lipid metabolism leading to cellular lipotoxicity (Mazar et al., 2014). </plain></SENT>
<SENT sid="324" pm="."><plain>In addition, a recent study identified a novel human lncRNA, lncHR1, which can decrease lipid accumulation both in vitro and in vivo by repressing the expression of SREBP-1c gene (Li et al., 2017). </plain></SENT>
<SENT sid="325" pm="."><plain>According to the results of co-expression network of AK012226–mRNAs, and the subsequent KEGG pathway and GO analyses, we found some pathways and GO terms to be likely linked to the pathogenesis of NAFLD, such as PPAR signaling pathway, biosynthesis of unsaturated fatty acids, bile secretion, and chemokine secretion. </plain></SENT>
<SENT sid="326" pm="."><plain>However, the underlying molecular mechanism of AK012226 in regulating lipid accumulation and in the pathogenesis of NAFLD has not yet been elucidated. </plain></SENT>
<SENT sid="327" pm="."><plain>Further investigation is needed to examine the role of AK012226 in the development of NAFLD. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec><title><text><SENT sid="328" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="329" pm="."><plain>We identified differentially expressed lncRNAs and mRNAs in diabetic NAFLD mice. </plain></SENT>
<SENT sid="330" pm="."><plain>Particularly, we identified a novel lncRNA, AK012226, this lncRNA was found to be closely related to lipid accumulation in the NCTC1469 NAFLD cell model. </plain></SENT>
</text></p></sec></SecTag><SecTag type="AUTH_CONT"><sec><title><text><SENT sid="331" pm="."><plain>Author Contributions </plain></SENT>
</text></title><p><text><SENT sid="332" pm="."><plain>XC, YX, and DZ generated data, data analysis, interpretation, and manuscript preparation. </plain></SENT>
<SENT sid="333" pm="."><plain>TC generated data, perform animal experiment, and data analysis. </plain></SENT>
<SENT sid="334" pm="."><plain>CG, GY, and KC data analysis, interpretation, and manuscript preparation. </plain></SENT>
<SENT sid="335" pm="."><plain>YZ analyzed data and generated figures and tables. </plain></SENT>
<SENT sid="336" pm="."><plain>JH data analysis, interpretation, and manuscript preparation. </plain></SENT>
<SENT sid="337" pm="."><plain>SL data analysis, interpretation, and manuscript preparation. </plain></SENT>
<SENT sid="338" pm="."><plain>YN data analysis, interpretation, and manuscript preparation. </plain></SENT>
<SENT sid="339" pm="."><plain>HY generated idea, study design, data analysis, interpretation, and manuscript writing. </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec><title><text><SENT sid="340" pm="."><plain>Conflict of Interest Statement </plain></SENT>
</text></title><p><text><SENT sid="341" pm="."><plain>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </plain></SENT>
</text></p></sec></SecTag></body><back><fn-group><SecTag type="ACK_FUND"><fn fn-type="financial-disclosure"><p><text4fund><text><SENT sid="342" pm="."><plain>Funding. This work was supported by National Natural Science Foundation of China (Grant Nos. 81372634 and 81600350), Guangdong Natural Science Funds for Distinguished Young Scholar (Grant No. S2013050014121), a research project from Guangdong Province Office of Education (Grant No. 2015KTSCX117), and Science and Technology Program of Guangzhou (Grant No. 201707010470). </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="343" pm="."><plain>We would like to thank Prof. </plain></SENT>
<SENT sid="344" pm="."><plain>Yu-Jui Yvonne Wan from the Department of Pathology and Laboratory Medicine UC Davis Medical Center for critically reading and editing the manuscript. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn id="fn01"><label>1</label><p><text><SENT sid="345" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.geneontology.org">www.geneontology.org</ext-link> </plain></SENT>
</text></p></fn><fn id="fn02"><label>2</label><p><text><SENT sid="346" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg/">http://www.genome.jp/kegg/</ext-link> </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="347" pm="."><plain>AdamsL. </plain></SENT>
<SENT sid="348" pm="."><plain>A.LympJ. </plain></SENT>
<SENT sid="349" pm="."><plain>F.St SauverJ.SandersonS. </plain></SENT>
<SENT sid="350" pm="."><plain>O.LindorK. </plain></SENT>
<SENT sid="351" pm="."><plain>D.FeldsteinA. (2005). The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 113–121. 10.1053/j.gastro.2005.04.014<?supplied-pmid 21768191?>16012941 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="352" pm="."><plain>AnsteeQ. </plain></SENT>
<SENT sid="353" pm="."><plain>M.McPhersonS.DayC. </plain></SENT>
<SENT sid="354" pm="."><plain>P. (2011). How big a problem is non-alcoholic fatty liver disease. BMJ 343:d3897 10.1136/bmj.d3897 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="355" pm="."><plain>ChenG.YuD.NianX.LiuJ.KoenigR. </plain></SENT>
<SENT sid="356" pm="."><plain>J.XuB. (2016). LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL). Sci. </plain></SENT>
<SENT sid="357" pm="."><plain>Rep. 6:35531. 10.1038/srep35531<?supplied-pmid 27759039?>27759039 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="358" pm="."><plain>ChenT.GuC.XueC.YangT.ZhongY.LiuS. (2017). LncRNA-uc002mbe.2 interacting with hnRNPA2B1 mediates AKT deactivation and p21 up-regulation induced by trichostatin in liver cancer cells. Front. </plain></SENT>
<SENT sid="359" pm="."><plain>Pharmacol. 8:669. 10.3389/fphar.2017.00669<?supplied-pmid 28993733?>28993733 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="360" pm="."><plain>ChenY.HuangH.XuC.YuC.LiY. (2017). Long non-coding RNA profiling in a non-alcoholic fatty liver disease rodent model: new insight into pathogenesis. Int. </plain></SENT>
<SENT sid="361" pm="."><plain>J. </plain></SENT>
<SENT sid="362" pm="."><plain>Mol. </plain></SENT>
<SENT sid="363" pm="."><plain>Sci. 18:E21. 10.3390/ijms18010021<?supplied-pmid 28275212?>28275212 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="364" pm="."><plain>DayC. </plain></SENT>
<SENT sid="365" pm="."><plain>P.JamesO. </plain></SENT>
<SENT sid="366" pm="."><plain>F. (1998). Steatohepatitis: a tale of two “hits”? Gastroenterology 114 842–845. 10.1016/S0016-5085(98)70599-29547102 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="367" pm="."><plain>DonnellyK. </plain></SENT>
<SENT sid="368" pm="."><plain>L.SmithC. </plain></SENT>
<SENT sid="369" pm="."><plain>I.SchwarzenbergS. </plain></SENT>
<SENT sid="370" pm="."><plain>J.JessurunJ.BoldtM. </plain></SENT>
<SENT sid="371" pm="."><plain>D.ParksE. </plain></SENT>
<SENT sid="372" pm="."><plain>J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. </plain></SENT>
<SENT sid="373" pm="."><plain>Clin. </plain></SENT>
<SENT sid="374" pm="."><plain>Invest. 115 1343–1351. 10.1172/JCI23621<?supplied-pmid 15864352?>15864352 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="375" pm="."><plain>GibbE. </plain></SENT>
<SENT sid="376" pm="."><plain>A.BrownC. </plain></SENT>
<SENT sid="377" pm="."><plain>J.LamW. </plain></SENT>
<SENT sid="378" pm="."><plain>L. (2011). The functional role of long non-coding RNA in human carcinomas. Mol. </plain></SENT>
<SENT sid="379" pm="."><plain>Cancer 10:38. 10.1186/1476-4598-10-38<?supplied-pmid 21489289?>21489289 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="380" pm="."><plain>JornayvazF. </plain></SENT>
<SENT sid="381" pm="."><plain>R.ShulmanG. </plain></SENT>
<SENT sid="382" pm="."><plain>I. (2012). Diacylglycerol activation of protein kinase cepsilon and hepatic insulin resistance. Cell Metab. 15 574–584. 10.1016/j.cmet.2012.03.005<?supplied-pmid 22560210?>22560210 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="383" pm="."><plain>KimH. </plain></SENT>
<SENT sid="384" pm="."><plain>M.LeeE. </plain></SENT>
<SENT sid="385" pm="."><plain>S.LeeB. </plain></SENT>
<SENT sid="386" pm="."><plain>R.YadavD.KimY. </plain></SENT>
<SENT sid="387" pm="."><plain>M.KoH. </plain></SENT>
<SENT sid="388" pm="."><plain>J. (2015). C-C chemokine receptor 2 inhibitor ameliorates hepatic steatosis by improving ER stress and inflammation in a type 2 diabetic mouse model. PLoS One 10:e0120711. 10.1371/journal.pone.0120711<?supplied-pmid 25816097?>25816097 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="389" pm="."><plain>KitadaM.OguraY.KoyaD. (2016). Rodent models of diabetic nephropathy: their utility and limitations. Int. </plain></SENT>
<SENT sid="390" pm="."><plain>J. </plain></SENT>
<SENT sid="391" pm="."><plain>Nephrol. </plain></SENT>
<SENT sid="392" pm="."><plain>Renovasc. </plain></SENT>
<SENT sid="393" pm="."><plain>Dis. 9 279–290. 10.2147/IJNRD.S10378427881924 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="394" pm="."><plain>LiD.ChengM.NiuY.ChiX.LiuX.FanJ. (2017). Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c. Int. </plain></SENT>
<SENT sid="395" pm="."><plain>J. </plain></SENT>
<SENT sid="396" pm="."><plain>Biol. </plain></SENT>
<SENT sid="397" pm="."><plain>Sci. 13 349–357. 10.7150/ijbs.16635<?supplied-pmid 28367099?>28367099 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="398" pm="."><plain>LiP.RuanX.YangL.KiesewetterK.ZhaoY.LuoH. (2015). A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab. 21 455–467. 10.1016/j.cmet.2015.02.004<?supplied-pmid 25738460?>25738460 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="399" pm="."><plain>MazarJ.ZhaoW.KhalilA. </plain></SENT>
<SENT sid="400" pm="."><plain>M.LeeB.ShelleyJ.GovindarajanS. </plain></SENT>
<SENT sid="401" pm="."><plain>S. (2014). The functional characterization of long noncoding RNA SPRY4-IT1 in human melanoma cells. Oncotarget 5 8959–8969. 10.18632/oncotarget.1863<?supplied-pmid 25344859?>25344859 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="402" pm="."><plain>MercerT. </plain></SENT>
<SENT sid="403" pm="."><plain>R.DingerM. </plain></SENT>
<SENT sid="404" pm="."><plain>E.MattickJ. </plain></SENT>
<SENT sid="405" pm="."><plain>S. (2009). Long non-coding RNAs: insights into functions. Nat. </plain></SENT>
<SENT sid="406" pm="."><plain>Rev. </plain></SENT>
<SENT sid="407" pm="."><plain>Genet. 10 155–159. 10.1038/nrg2521<?supplied-pmid 19188922?>19188922 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="408" pm="."><plain>MichelottiG. </plain></SENT>
<SENT sid="409" pm="."><plain>A.MachadoM. </plain></SENT>
<SENT sid="410" pm="."><plain>V.DiehlA. </plain></SENT>
<SENT sid="411" pm="."><plain>M. (2013). NAFLD, NASH and liver cancer. Nat. </plain></SENT>
<SENT sid="412" pm="."><plain>Rev. </plain></SENT>
<SENT sid="413" pm="."><plain>Gastroenterol. </plain></SENT>
<SENT sid="414" pm="."><plain>Hepatol. 10 656–665. 10.1038/nrgastro.2013.183<?supplied-pmid 24080776?>24080776 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="415" pm="."><plain>Neuschwander-TetriB. </plain></SENT>
<SENT sid="416" pm="."><plain>A. (2010). Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52 774–788. 10.1002/hep.23719<?supplied-pmid 20683968?>20683968 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="417" pm="."><plain>Non-alcoholic Fatty Liver Disease Study GroupLonardoBellentaniA.ArgoS.BallestriC. </plain></SENT>
<SENT sid="418" pm="."><plain>K.ByrneS. </plain></SENT>
<SENT sid="419" pm="."><plain>C. </plain></SENT>
<SENT sid="420" pm="."><plain>D. (2015). Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig. </plain></SENT>
<SENT sid="421" pm="."><plain>Liver Dis. 47 997–1006. 10.1016/j.dld.2015.08.004<?supplied-pmid 26454786?>26454786 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="422" pm="."><plain>Portillo-SanchezP.BrilF.MaximosM.LomonacoR.BiernackiD.OrsakB. (2015). High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J. </plain></SENT>
<SENT sid="423" pm="."><plain>Clin. </plain></SENT>
<SENT sid="424" pm="."><plain>Endocrinol. </plain></SENT>
<SENT sid="425" pm="."><plain>Metab. 100 2231–2238. 10.1210/jc.2015-1966<?supplied-pmid 25885947?>25885947 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="426" pm="."><plain>PrietoC.RisueñoA.FontanilloC.De las RivasJ. (2008). Human gene coexpression landscape: confident network derived from tissue transcriptomic profiles. PLoS One 3:e3911. 10.1371/journal.pone.0003911<?supplied-pmid 19081792?>19081792 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="427" pm="."><plain>PujanaM. </plain></SENT>
<SENT sid="428" pm="."><plain>A.HanJ. </plain></SENT>
<SENT sid="429" pm="."><plain>D.StaritaL. </plain></SENT>
<SENT sid="430" pm="."><plain>M.StevensK. </plain></SENT>
<SENT sid="431" pm="."><plain>N.TewariM.AhnJ. </plain></SENT>
<SENT sid="432" pm="."><plain>S. (2007). Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. </plain></SENT>
<SENT sid="433" pm="."><plain>Genet. 39 1338–1349. 10.1038/ng.2007.2<?supplied-pmid 17922014?>17922014 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="434" pm="."><plain>RecciaI.KumarJ.AkladiosC.VirdisF.PaiM.HabibN. (2017). Non-alcoholic fatty liver disease: a sign of systemic disease. Metabolism 72 94–108. 10.1016/j.metabol.2017.04.011<?supplied-pmid 28641788?>28641788 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="435" pm="."><plain>RinnJ. </plain></SENT>
<SENT sid="436" pm="."><plain>L.ChangH. </plain></SENT>
<SENT sid="437" pm="."><plain>Y. (2012). Genome regulation by long noncoding RNAs. Annu. </plain></SENT>
<SENT sid="438" pm="."><plain>Rev. </plain></SENT>
<SENT sid="439" pm="."><plain>Biochem. 81 145–166. 10.1146/annurev-biochem-051410-092902<?supplied-pmid 22663078?>22663078 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="440" pm="."><plain>SanchesS. </plain></SENT>
<SENT sid="441" pm="."><plain>C.RamalhoL. </plain></SENT>
<SENT sid="442" pm="."><plain>N.AugustoM. </plain></SENT>
<SENT sid="443" pm="."><plain>J.daSilva DMRamalhoF. </plain></SENT>
<SENT sid="444" pm="."><plain>S. (2015). Nonalcoholic steatohepatitis: a search for factual animal models. Biomed. </plain></SENT>
<SENT sid="445" pm="."><plain>Res. </plain></SENT>
<SENT sid="446" pm="."><plain>Int. 2015:574832. 10.1155/2015/574832<?supplied-pmid 26064924?>26064924 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="447" pm="."><plain>ShiX.SunM.LiuH.YaoY.SongY. (2013). Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 339 159–166. 10.1016/j.canlet.2013.06.013<?supplied-pmid 23791884?>23791884 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="448" pm="."><plain>SuM. </plain></SENT>
<SENT sid="449" pm="."><plain>L.HeY.LiQ. </plain></SENT>
<SENT sid="450" pm="."><plain>S.ZhuB. </plain></SENT>
<SENT sid="451" pm="."><plain>H. (2016). Efficacy of acetylshikonin in preventing obesity and hepatic steatosis in db/db mice. Molecules 21:E976. 10.3390/molecules21080976<?supplied-pmid 27483220?>27483220 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="452" pm="."><plain>SunC.LiuX.YiZ.XiaoX.YangM.HuG. (2015). Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease. IUBMB Life 67 847–852. 10.1002/iub.1442<?supplied-pmid 26472541?>26472541 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="453" pm="."><plain>TeschG. </plain></SENT>
<SENT sid="454" pm="."><plain>H.LimA. </plain></SENT>
<SENT sid="455" pm="."><plain>K. (2011). Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am. </plain></SENT>
<SENT sid="456" pm="."><plain>J. </plain></SENT>
<SENT sid="457" pm="."><plain>Physiol. </plain></SENT>
<SENT sid="458" pm="."><plain>Renal Physiol. 300 F301–F310. 10.1152/ajprenal.00607.2010<?supplied-pmid 21147843?>21147843 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="459" pm="."><plain>WangK. </plain></SENT>
<SENT sid="460" pm="."><plain>C.ChangH. </plain></SENT>
<SENT sid="461" pm="."><plain>Y. (2011). Molecular mechanisms of long noncoding RNAs. Mol. </plain></SENT>
<SENT sid="462" pm="."><plain>Cell 43 904–914. 10.1016/j.molcel.2011.08.018<?supplied-pmid 21925379?>21925379 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="463" pm="."><plain>WangX.SongX.GlassC. </plain></SENT>
<SENT sid="464" pm="."><plain>K.RosenfeldM. </plain></SENT>
<SENT sid="465" pm="."><plain>G. (2011). The long arm of long noncoding RNAs: roles as sensors regulating gene transcriptional programs. Cold Spring Harb. </plain></SENT>
<SENT sid="466" pm="."><plain>Perspect. </plain></SENT>
<SENT sid="467" pm="."><plain>Biol. 3:a003756. 10.1101/cshperspect.a003756<?supplied-pmid 20573714?>20573714 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="468" pm="."><plain>WHO (2014). Global Health Observatory (GHO) Data - OBESITY and Overweight. Geneva: WHO. </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="469" pm="."><plain>WiluszJ. </plain></SENT>
<SENT sid="470" pm="."><plain>E.SunwooH.SpectorD. (2009). Spector, long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 23 1494–1504. 10.1101/gad.1800909<?supplied-pmid 19571179?>19571179 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="471" pm="."><plain>YangH.ZhongY.XieH.LaiX.XuM.NieY. (2013). Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin-induced apoptosis of liver cancer cells. Biochem. </plain></SENT>
<SENT sid="472" pm="."><plain>Pharmacol. 85 1761–1769. 10.1016/j.bcp.2013.04.020<?supplied-pmid 23643933?>23643933 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="473" pm="."><plain>YounossiZ. </plain></SENT>
<SENT sid="474" pm="."><plain>M.KoenigA. </plain></SENT>
<SENT sid="475" pm="."><plain>B.AbdelatifD.FazelY.HenryL.WymerM. (2016). Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 73–84. 10.1002/hep.28431<?supplied-pmid 26707365?>26707365 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
